pharmaceutical investing CMS Grants Progenics New Technology Add-On Payment for Inpatient Use of AZEDRA
pharmaceutical investing Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy
pharmaceutical investing Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration
pharmaceutical investing Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
pharmaceutical investing Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
Brunswick Exploration Closes First Tranche of Non-Brokered Private Placement for Gross Proceeds of $4,195,000
LaFleur Minerals Bolsters Executive Team and Announces Webinar to Present Positive PEA for Beacon Gold Mill Restart
